Brain-derived neurotrophic factor ameliorates learning deficits in a rat model of Alzheimer's disease induced by aβ1-42

PLoS One. 2015 Apr 7;10(4):e0122415. doi: 10.1371/journal.pone.0122415. eCollection 2015.

Abstract

An emerging body of data suggests that the early onset of Alzheimer's disease (AD) is associated with decreased brain-derived neurotrophic factor (BDNF). Because BDNF plays a critical role in the regulation of high-frequency synaptic transmission and long-term potentiation in the hippocampus, the up-regulation of BDNF may rescue cognitive impairments and learning deficits in AD. In the present study, we investigated the effects of hippocampal BDNF in a rat model of AD produced by a ventricle injection of amyloid-β1-42 (Aβ1-42). We found that a ventricle injection of Aβ1-42 caused learning deficits in rats subjected to the Morris water maze and decreased BDNF expression in the hippocampus. Chronic intra-hippocampal BDNF administration rescued learning deficits in the water maze, whereas infusions of NGF and NT-3 did not influence the behavioral performance of rats injected with Aβ1-42. Furthermore, the BDNF-related improvement in learning was ERK-dependent because the inhibition of ERK, but not JNK or p38, blocked the effects of BDNF on cognitive improvement in rats injected with Aβ1-42. Together, our data suggest that the up-regulation of BDNF in the hippocampus via activation of the ERK signaling pathway can ameliorate Aβ1-42-induced learning deficits, thus identifying a novel pathway through which BDNF protects against AD-related cognitive impairments. The results of this research may shed light on a feasible therapeutic approach to control the progression of AD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / chemically induced
  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / enzymology
  • Alzheimer Disease / physiopathology*
  • Amyloid beta-Peptides / toxicity*
  • Animals
  • Brain-Derived Neurotrophic Factor / administration & dosage
  • Brain-Derived Neurotrophic Factor / metabolism
  • Brain-Derived Neurotrophic Factor / pharmacology*
  • Brain-Derived Neurotrophic Factor / therapeutic use
  • Cognition / drug effects
  • Disease Models, Animal
  • Enzyme Activation / drug effects
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Hippocampus / drug effects
  • Hippocampus / metabolism
  • Hippocampus / physiopathology
  • Humans
  • Injections
  • Learning / drug effects*
  • Male
  • Memory / drug effects
  • Peptide Fragments / toxicity*
  • Rats
  • Rats, Sprague-Dawley
  • Spatial Learning / drug effects
  • Up-Regulation / drug effects

Substances

  • Amyloid beta-Peptides
  • Brain-Derived Neurotrophic Factor
  • Peptide Fragments
  • amyloid beta-protein (1-42)
  • BDNF protein, human
  • Extracellular Signal-Regulated MAP Kinases

Grants and funding

This work was supported by Zhengzhou Science & Technology Basic Research Program (No. 340600531794) and by Henan Science & Technology Basic Research Program (No.122300410365). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.